Aurora Spine Reports Record Q2 2025 Financial Results and Product Milestones

The latest announcement is out from Aurora Spine ( (TSE:ASG) ).

Aurora Spine Corporation reported a record second quarter for 2025, with revenues increasing by 10.2% to $4.5 million. The company achieved significant milestones, including surpassing 2,500 procedures using its SiLO SI Joint Fusion System and 1,500 surgeries with DEXA-C. Aurora is preparing to launch its new FDA-cleared Hydra A.E.R.O. product and has seen a 70% increase in cervical sales, primarily due to the DEXA-C implant. The company is also focusing on improving its presence in the lumbar spine field with the upcoming launch of the DEXA-L series. Management highlighted the company’s strong operational performance and continued efforts to educate the marketplace about its minimally invasive procedures.

The most recent analyst rating on (TSE:ASG) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Aurora Spine stock, see the TSE:ASG Stock Forecast page.

Spark’s Take on TSE:ASG Stock

According to Spark, TipRanks’ AI Analyst, TSE:ASG is a Neutral.

Aurora Spine’s overall stock score is driven by its strong corporate events, showcasing innovation and strategic growth initiatives. However, financial performance and valuation concerns, including ongoing losses and high leverage, weigh down the score. Technical analysis indicates a bearish trend, further impacting the overall assessment.

To see Spark’s full report on TSE:ASG stock, click here.

More about Aurora Spine

Aurora Spine Corporation is a leader in spine and interventional spine technology, focusing on improving spinal surgery outcomes. The company is involved in the development and commercialization of minimally invasive procedures and proprietary product platforms for the medical industry.

Average Trading Volume: 32,453

Technical Sentiment Signal: Sell

Current Market Cap: C$22.64M

See more data about ASG stock on TipRanks’ Stock Analysis page.